Amgen Inc. $AMGN Stock: Sumitomo Mitsui DS Asset Management Company Ltd Boosts Stake

Sumitomo Mitsui DS Asset Management Company Ltd increased its position in Amgen Inc. (NASDAQ:AMGN) by 0.9% in the 3rd quarter, HoldingsChannel reports. The fund owned 324,455 shares of the medical research company’s stock after purchasing an additional 2,758 shares during the period. Amgen accounts for about 0.9% of Sumitomo Mitsui DS Asset Management Company Ltd’s holdings, making the stock its 20th biggest position. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Amgen were worth $136,761,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the company. Wellington Altus USA Inc. lifted its holdings in Amgen by 72.3% during the second quarter. Wellington Altus USA Inc. now owns 81 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 34 shares during the last quarter. Tower View Wealth Management LLC boosted its position in Amgen by 331.6% during the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after purchasing an additional 63 shares during the period. Nvwm LLC increased its stake in shares of Amgen by 412.5% in the third quarter. Nvwm LLC now owns 82 shares of the medical research company’s stock worth $35,000 after purchasing an additional 66 shares in the last quarter. Security National Bank of Sioux City Iowa IA purchased a new position in shares of Amgen in the second quarter worth about $36,000. Finally, Steph & Co. bought a new stake in shares of Amgen in the third quarter valued at approximately $42,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Amgen Stock Down 1.7%

AMGN stock opened at $424.94 on Tuesday. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The firm has a market capitalization of $229.74 billion, a PE ratio of 26.41, a PEG ratio of 3.17 and a beta of 0.41. Amgen Inc. has a twelve month low of $288.00 and a twelve month high of $447.03. The stock has a 50-day simple moving average of $415.69 and a two-hundred day simple moving average of $375.45.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, beating the consensus estimate of $5.62 by $0.67. Amgen had a return on equity of 124.14% and a net margin of 22.95%. The firm had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. During the same period in the prior year, the business posted $6.02 earnings per share. The company’s revenue was up 9.5% on a year-over-year basis. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, equities analysts predict that Amgen Inc. will post 22.94 EPS for the current fiscal year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were paid a $2.52 dividend. The ex-dividend date was Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.4%. Amgen’s dividend payout ratio is currently 62.65%.

Insider Activity at Amgen

In other Amgen news, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Nancy Grygiel sold 2,970 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total transaction of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 6,222 shares of company stock worth $2,540,926 over the last quarter. Corporate insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Weiss Ratings upgraded shares of Amgen from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 8th. Piper Sandler lifted their price objective on shares of Amgen from $427.00 to $457.00 and gave the company an “overweight” rating in a research note on Thursday, August 20th. Wall Street Zen upgraded shares of Amgen from a “hold” rating to a “buy” rating in a research note on Sunday. BMO Capital Markets lowered their target price on shares of Amgen from $450.00 to $415.00 and set a “market perform” rating on the stock in a report on Monday, October 12th. Finally, Oppenheimer restated an “outperform” rating on shares of Amgen in a research report on Wednesday, September 23rd. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $387.93.

Key Stories Impacting Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Australia’s Pharmaceutical Benefits Advisory Committee conditionally backed IMDELLTRA, Amgen’s treatment for extensive-stage small-cell lung cancer. If final requirements are met, the recommendation could improve patient access and create an additional commercial opportunity for the drug. PBAC conditionally backs IMDELLTRA
• Positive Sentiment: Exchange-traded funds reportedly purchased approximately $19.4 million of Amgen shares on October 15, indicating institutional demand that may provide some technical support for the stock. ETFs bought Amgen shares
• Positive Sentiment: Recent analyst coverage includes a reported Wall Street Zen rating upgrade, while broader commentary highlights Amgen’s established portfolio, dividend, and potential next growth wave. The company’s latest reported quarter also exceeded earnings and revenue expectations, supporting the underlying financial case. Amgen rating upgraded
• Neutral Sentiment: Amgen has attracted increased attention on Zacks and other investment platforms. The coverage is largely a recap of factors investors should monitor—including pipeline execution, valuation, competition, and future earnings—rather than a new fundamental announcement. Amgen attracting investor attention
• Negative Sentiment: Investor commentary emphasizes that Amgen has reliable cash flow and a dividend but now needs stronger growth. That concern may be weighing on sentiment, particularly with the stock near its 52-week high and investors expecting newer products and pipeline programs to offset slower growth from mature medicines. Amgen needs growth

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.